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The validity of amyloid-β peptide (Aβ1−42) intrahippocampal injection, as an animal model of Alzheimer’s disease (AD), has
previously been considered in terms of inﬂammatory reactivity and neuronal damage. In this work, we have extended the testing
of the animal model to vasculature by comparison of selected properties of microvessels in vivo with those in human AD brain
tissue. The injection of Aβ1−42,r e l a t i v et oc o n t r o lP B S( p h o s p h a t eb u ﬀered saline), increased the mean number of microvessels
and diminished the mean length of microvessels in the molecular layer of dentate gyrus. The animal model showed Aβ1−42, but not
PBS, injection was associated with abnormalities in morphology of microvessels which were characterized as looping, fragmented,
knob-like, uneven, and constricted. In particular, numbers of constricted microvessels, deﬁned as vessels with diameters less than
3μm, were considerably enhanced for Aβ1−42, compared to PBS, injection. In comparison, human AD brain demonstrated an
elevated number of microvessels with a diminished mean length relative to nondemented (ND) brain. Additionally, microvessel
perturbations in AD brain showed a similar pattern of morphological abnormalities to those observed in Aβ1−42-injected rat
hippocampus. Constricted microvessels were a prominent feature of AD brain but were rarely observed in ND tissue. These results
providetheﬁrstevidencethatapeptide-injectionanimalmodelexhibitsacommonalityinperturbationsofmicrovesselscompared
with those evident in AD brain.
1.Introduction
A host of animal models have been proposed with relevance
to modeling the pathological features which characterize
Alzheimer’s disease (AD) brain. In order to test the validity
of the animal models, properties and predictions from
animal models can be compared with the characteristic
features present in AD brains. These features involve a
broad spectrum of altered properties from those of control
nondemented (ND) individuals including the presence of
enhanced deposits of amyloid-β peptide (Aβ)[ 1], neuroﬁb-
rillarytangles(NFTs)[2],abnormalitiesinvasculature[3–5],
evidence for ongoing chronic inﬂammation [6, 7], and loss
of neurons and synaptic connectivity [8]. Advancement, ﬁne
tuning, or rejection of animal models involves a rigorous and
complexcomparativeprocess concerningthetesting ofmany
variables.
Intrahippocampal injection of Aβ1−42 in rat brain has
been suggested as an animal model which emphasizes the
inﬂammatory reactivity present in human AD brain [9].
This model shows marked enhancement of microgliosis
in response to peptide relative to control injections of
PBS (phosphate buﬀered saline) vehicle or reverse pep-
tide (Aβ42−1). In addition, hippocampal neuronal loss is
signiﬁcantly increased with Aβ1−42, compared to control,
injection. Importantly, drug inhibition of microglial inﬂam-
matory responses has a demonstrated eﬃcacy for conferring
neuroprotection [10–12]. Comparison at the molecular
and cellular levels has included the ﬁnding that enhanced
expression of the purinergic ionotropic P2X7 receptor in2 International Journal of Alzheimer’s Disease
activated microglia occurred similarly both in the animal
model and in AD brain tissue [13].
Another feature of the Aβ1−42 rat model is evidence
for an inﬂammatory response involving altered vasculature
including a leaky blood-brain barrier (BBB). In this case
Aβ1−42 induced an increased permeability of BBB compared
to control PBS injection allowing inﬁltration of plasma
protein into parenchymal brain regions [12]. Elevated
b r a i nﬁ b r i n o g e nw a ss u g g e s t e da sa na m p l i f y i n gf a c t o rf o r
microglial activation and inﬂammatory reactivity. Overall,
the results from in vivo studies indicated that Aβ1−42 injec-
tion elicited microglial reactivity which may be associated
with a weakened BBB. These ﬁndings enhanced creditability
of the model for predicting vascular changes since evidence
has suggested BBB in AD brain may be damaged [14].
The overall purpose of the present study was to test
and extend the utility of Aβ peptide intrahippocampal
injection as an animal model of AD. The present work was
speciﬁcally designed to compare vascular perturbations in
the animal model with speciﬁc microvessel changes and
irregularities evident between AD and ND brain tissue.
The comparison has included numbers and lengths of
microvessels and abnormalities in microvessels including
vessels with constricted diameters.
2.MaterialsandMethods
2.1. Animal Model Study. All protocols involved studies
on male Sprague-Dawley rats and were approved by the
University of British Columbia Animal Care Ethics Com-
mittee. The relevance of using intrahippocampal Aβ1−42
as an animal model of AD has been reviewed [9], and
the overall procedures employed in use of the model have
been detailed in previous work from this laboratory [10–
13]. Brieﬂy, stereotaxic injection of peptide (2nmol of full
length Aβ1−42; California Peptide, Napa, CA) or control
(PBS) was performed into the dentate gyrus region of
hippocampus (AP: −3.3mm, ML: −1.6mm, DV: −3.2mm).
Injection of peptide, compared with PBS, precipitates an
enhancedmicroglialinﬂammatoryresponseaccompaniedby
substantial loss of hippocampal neurons.
2.2. Tissue Preparation and Immunohistochemistry. At one
week postinjection brains were removed and postﬁxed and
cryoprotected prior to cutting into 40μm sections. Free-
ﬂoating sections were processed for immunohistochemistry
with sections incubated overnight at 4◦Cw i t hp r i m a r y
antibodies to rat endothelial cell antigen (RECA-1, 1:1000;
Serotec, Oxford, UK) or laminin (1:1000; Sigma, St.
Louis, MO). The use of RECA-1 and laminin for staining
of microvessels has been detailed in [12]. Sections were
incubated in Alexa Fluor conjugated secondary antibodies
(1:200; Invitrogen, Carlsbad, CA) for immunoﬂuorescence
staining. In immunostaining controls, primary antibody was
omittedinallstainingprocedures.Thetissueswereexamined
under a Zeiss axioplan-2 ﬂuorescent microscope (Zeiss, Jena,
Germany) using a DVC camera (Diagnostic Instruments,
SterlingHeights,MI)withNorthernEclipsesoftware(Empix
Imaging, Mississauga, ON, Canada). Quantitative assess-
ment was performed under a constant predeﬁned light set-
ting. The digitized images were analyzed using NIH ImageJ
1.37bsoftware(NationalInstituteofHealth,Bethesda,MD).
Fourcoronalhippocampalsections(200μmapart)wereused
for quantitative analysis (detailed procedures in [10–13]). In
each stained section, four nonoverlapping ﬁelds within the
granule cell layer and molecular layer regions were selected
(magniﬁcation of 40x). Density and lengths of microvessels
were measured in molecular layer regions of dentate gyrus;
mean values for these variables were found from averaged
values over 1.3mm2 areas. In some experiments numbers of
microvessels with narrow diameters were measured. These
microvessels are deﬁned by diameters ≤3μma n dt e r m e d
constricted.
2.3. Human Brain Tissue. Postmortem medial temporal
cortical (MTC) tissue was obtained from the Kinsmen
Laboratory brain bank at the University of British Columbia
(Vancouver, BC, Canada). Protocols for use of human tissue
wereinaccordancewithethicalguidelines establishedbyThe
University of British Columbia. Brain tissue from MTC was
obtained from 9ND cases (75–99 years of age; mean 83.0 ±
2.5) and 9AD cases (65–90 years of age; mean 76.2 ± 2.8).
Neuropathological criteria were used in the classiﬁcation
of brain tissue with ND cases showing no clinical or
pathological history of dementia or other neurological disor-
ders. AD cases were characterized by immunohistochemical
assessment of the density of plaques and NFT in limbic and
neocortical areas (including hippocampus, amygdala, and
frontal,temporal,parietal,andoccipitalcortex).AllADcases
conformed to criteria provided by the National Institute on
Aging and Reagan Institute [15].
2.4. Immunohistochemistry. The protocols used for laminin
immunohistochemical staining in AD and ND brain tissue
have been detailed [12, 16]. Brieﬂy, free-ﬂoating sections
with40μm thickness were cut from medial temporal cortical
tissue. Sections were then transferred into PBS/Triton-X
solution and incubated overnight at room temperature with
laminin (1:1000, Sigma). Biotinylated secondary antibody
was applied followed by incubation in avidin-biotinylated
horseradish peroxidase complex with labeling visualized by
incubation in diaminobenzidine (DAB) solutions. Sections
were then washed and mounted on glass slides, air-dried,
and coverslipped; immunostaining controls were performed
using standard procedures omitting primary antibodies;
under these conditions no control staining was observed
for any marker. The images were acquired using a light
microscope (Olympus BX51) and a digital DP71 cam-
era (Olympus, Center Valley, PA). Detailed quantiﬁcation
method has been described previously [16]. Four sections
in the grey matter of medial temporal cortex were used for
analysis with ﬁelds separated by ﬁxed distances to ensure
no overlap between image areas. Laminin staining was used
to measure numbers and lengths of microvessels in 1mm2
cortical areas. Constricted microvessels, with diameters
≤3μm, were also measured in the cortical brain regions.International Journal of Alzheimer’s Disease 3
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Figure 1: Representative patterns of RECA-1 staining in rat hippocampus. (a) Microvessels in control (PBS) injected rat hippocampus
(left panel) and microvessels in Aβ1−42-injected hippocampus (right panel). Scale bar is for 70μm. (b) Bar graph for the number of
microvessels/mm2 (n = 5e a c h ) .( c )B a rg r a p hf o rm i c r o v e s s e ll e n g t h( n = 5 each). ∗P ≤ 0.05 for Aβ1−42 versus PBS.
Quantitative assessment was performed under a constant
predeﬁned light setting. The digitized images were analyzed
using NIH ImageJ 1.37b software (National Institute of
Health, Bethesda, MD).
2.5. Statistical Analysis. Values are expressed as means
± SEM. Statistical signiﬁcance was assessed by one-way
ANOVA, followed by Student-Newman-Keuls multiple com-
parison test (GraphPad Prism 3.0). Signiﬁcance was set at
P<0.05.
3. Results
3.1. Microvessels in the Aβ1−42 Intrahippocampal
Injection Animal Model
3.1.1. Numbers and Lengths of Microvessels. Typical patterns
of microvessel staining (RECA-1 marker) are shown for
control PBS vehicle (Figure 1(a),l e f tp a n e l )a n dA β1−42
(Figure 1(a), right panel) at 7d after injection in rat
hippocampus. The area of staining was for the molecular
layer of dentate gyrus. Although morphological diﬀerences
were observed between the two animal groups (see below),
the most evident diﬀerence was the increased number of
microvessels in peptide-injected brain. The numbers of
microvessels/mm2 for control and Aβ1−42 are presented
in the bar graph of Figure 1(b). Also shown are the
mean lengths of microvessels for the two animal groups
(Figure 1(c)). Overall (n = 5e a c hf o rc o n t r o la n dA β1−42
group), peptide-injected brain demonstrated a 42 ± 7%
increase in numbers of microvessels, normalized to area,
comparedtocontrolPBSinjection.Meanlengthofmicroves-
sels was signiﬁcantly decreased (by 27 ± 4%) in Aβ1−42,
compared with PBS, injection. Although the increase in
microvessel density could indicate angiogenesis, it should be
noted that a speciﬁc angiogenic marker would be required to
assess formation of new blood capillaries in peptide-injected
brain.
3.1.2. Morphology of Microvessels in Aβ1−42-Injected Rat Hip-
pocampus. Inspectionofthemorphology ofmicrocapillaries
indicated enhanced irregularities in vessels from peptide-
injected hippocampus compared with control (Figure 2).
For example, fragmented microvessels were much more
common after Aβ1−42 compared with PBS, injection. Other
microvessel abnormalities which were relatively abundant
following peptide injection included constricted microcap-
illaries (see below) and microvessels with looping, knob-like,4 International Journal of Alzheimer’s Disease
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Figure 2: Morphology of microvessels stained with RECA-1in Aβ1−42-injected hippocampus. Panels show morphological features including
fragments, looping microvessels, and vessels with knob-like and uneven diameters. The scale bar represents 40μm.
andunevenappearances(Figure 2).Althoughthesemorpho-
logical categories largely reﬂect subjective descriptions, such
characteristics were not commonly observed in PBS-injected
rat hippocampus.
3.1.3. Constricted Microvessels in Aβ1−42-Injected Rat Hip-
pocampus. A general ﬁnding in peptide-injected hippocam-
pus was the appearance of constricted microvessels. These
narrow microcapillaries (laminin staining, Figure 3(a))
exhibited 3μm or less in diameters and often showed
attachment to larger width microvessels. In some cases
the constricted microcapillaries formed a bridge between
adjacent larger blood vessels. Overall (n = 5, Figure 3(b)),
14 ± 3.1% of microvessels in Aβ1−42-injected rat hippocam-
pus demonstrated constricted diameters; the corresponding
valueinPBS-injectedbrainwas4 ±1.4%.Atpresent,itisnot
known if the constricted microvessels represent angiogenic
vessels or possibly a population of damaged vessels.
3.2. Microvessels in AD and ND Brain Tissue
3.2.1. Numbers and Lengths of Microvessels. Remodeling of
microvasculature was examined in cortical tissue from ND
and AD individuals. Representative laminin immunore-
activity (ir) for microvessels from the two categories of
cases is presented in Figure 4(a) (ND, left panel; AD, right
panel). Microvessels in ND showed a typical pattern of
linear shape with little evidence for multiple branching from
the primary vessel. A diﬀerent pattern of microvasculature
was manifest in AD tissue with microvessels commonly
exhibiting considerable variability in length and diameter. In
particular, AD tissue commonly demonstrated microvessels
with short lengths (fragments) and sections with narrow
and constricted diameters (see below); such properties were
largelyabsentinNDcases.Thenumberofmicrovessels/mm2
w a sd e t e r m i n e df o rN Da n dA Dc o r t i c a lt i s s u e .T h er e s u l t s
(Figure 4(b)) show that microvessel number was 72 ± 9%
higher in AD, relative to ND, brain (n = 9 cases each for
ND and AD); this diﬀerence was signiﬁcant. Mean length
of microvessels was signiﬁcantly lower, by 18 ± 5%, in AD,
relative to ND, tissue (Figure 4(c)).
3.2.2. Morphological Properties of Vessels in AD Tissue. A
pattern of altered microvessel morphology was observed
between vasculature in AD and ND brain tissue. In particu-
lar, AD microvessels demonstrated a considerable variation
of morphological shapes including thin fragments and
nonlinear segments. Examples of speciﬁc abnormalities in
AD microvessels are presented in Figure 5.F r a g m e n t e da n d
narrow (see below) microvessels were particularly evident
in AD tissue with vessels exhibiting ring-like morphology.
Additionally, AD microvessels often presented as unevenInternational Journal of Alzheimer’s Disease 5
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Figure 3: Constricted microvessels in Aβ1−42-injected hippocampus. (a) Laminin immunoreactivity showing examples of constricted
microvessels (indicated by arrows). The scale bar is for 50μm. (b) Bar graph showing % of constricted microvessels for PBS control and
Aβ1−42 injection (n = 5). ∗P ≤ 0.05 for Aβ1−42 versus PBS.
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Figure 4: Representative laminin staining for microvessels in human ND and AD brain tissue. (a) Microvessels in ND (left panel) and AD
(right panel). The scale bar represents 100μm. (b) Bar graph for mean numbers of microvessels/mm2.( c )B a rg r a p hf o rm i c r o v e s s e ll e n g t h
(μm) (ND, n = 9; AD; n = 9); ∗P ≤ 0.0 5f o rA Dv e r s u sN D .6 International Journal of Alzheimer’s Disease
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Figure 5: Physical and morphological properties of microvessels in AD brain tissue. The panels show microvessels with fragments, looping
pattern, knob-like structure, and uneven structure. The scale bar is for 30μm.
diameters with areas of dilation and formation of knob-like
structures. Although ND cases demonstrated microvessels
with similar features to those described in AD tissue, their
frequency of appearance was scarce. Previous work has
documented morphological features and abnormalities in
microvesselsintissueobtainedfromADindividuals[17–19].
3.2.3. Constricted Vessels in AD Tissue. A common ﬁnding
in AD cases was the appearance of constricted microvessels
in the temporal cortex as shown in the representative
laminin staining (arrows, Figure 6(a)); examples of con-
stricted microvessels were much less evident in ND cases. As
for the animal model, microvessel constriction was deﬁned
as a diameter equal to, or less than, 3μm. Overall (ND,
n = 9; AD, n = 9), constricted microvessels in ND cases
comprised only 3.9 ± 2.2% of total vessels (Figure 6(b)).
The corresponding value in AD tissue was 23.6 ± 6.7%
of microvessels exhibiting constriction. Thus microvessel
constriction appears as a prominent characteristic in AD
brain, a distinguishing feature diﬀerentiating vasculature in
diseased tissue from ND cases.
4. Discussion
The primary aim of this work was to compare microvessel
number, length, and morphological properties between
Aβ1−42 and control PBS intrahippocampal injection in a
rat model of AD with the same variables in human AD
and ND brain tissue. The overall results show a similar
pattern of microvessel perturbations in Aβ peptide-injected
rat brain as present in AD brain. The changes include
an increased mean number and diminished mean length
of microvessels and prominent expression of microvessel
abnormalities in peptide-injected rat and in AD brain tissue
compared with PBS-injected and ND brain. The abnormal
properties include the presence of constricted microvessels
which were largely absent in controls. These results extend
previous ﬁndings that the Aβ1−42 animal model exhibits
characteristics similar to those in AD brain including an
altered BBB permeability, enhanced inﬂammatory reactivity,
a n dn e u r o n a ll o s s[ 12].
The increased density of microvessels in Aβ1−42 versus
PBS (rat) and AD versus ND (human) could suggest
angiogenic activity in AD brain. However, a proviso is
that a speciﬁc marker for angiogenesis is not well deﬁned.
Although increased expressions of laminin [20, 21]a n d
integrin αvβ3[ 22, 23] have been suggested as indicators of
angiogenesistheyarenotspeciﬁcmarkerswhichdiﬀerentiate
between newly formed and existing capillaries. Nevertheless,
a consistent enhancement in microvessel number was a
commonpatternofchangewithAβ1−42 injection(versusPBS
in the animal model) and in AD (versus ND) brain tissue.
It is possible that angiogenic activity could be associated
with increased leakiness of blood vessels. In this regard,
extravasation of plasma proteins including albumin has been
measured in the peptide-injected rat hippocampus [10].
The possibility of angiogenesis in AD brain is supported
by the ﬁnding that a spectrum of proangiogenic factors
is elevated in AD pathology [24]. One particular highly
potent angiogenic agent is vascular endothelial growth factorInternational Journal of Alzheimer’s Disease 7
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Figure 6: Constricted microvessels in AD brain tissue. (a) The arrows indicate constricted microvessels; scale bar is for 30μm. (b) Bar graph
shows % of constricted, relative to total, microvessels for the diﬀerent cases (ND, n = 9; AD; n = 9); ∗P ≤ 0.0 5f o rA Dv e r s u sN D .
(VEGF). Increased levels of VEGF are reported in microglia
obtained from AD patients and in human microglia exposed
to Aβ1−42 [11]. Furthermore, intrathecal levels of VEGF
are increased in AD patients relative to controls [25]. In
addition, APP23 transgenic mice show increased formation
of new vessels which was inhibited using an antagonist for
VEGF [26]. Taken together, accumulating evidence suggests
appropriateconditionsexisttosupportangiogenicactivityin
AD brain.
Particular morphological irregularities were evident in
Aβ1−42-injected dentate gyrus and AD brain tissue and
largely absent with PBS injection and in ND brain. These
abnormalities were characterized as fragmented, looping,
knob-like, uneven, and constricted. Typical representations
of these features are shown for Aβ1−42 animal treatment
(Figure 2) and for human AD cases (Figure 5). Since
constricted microvessels (diameters ≤ 3μm) were clearly
deﬁnable compared with the other abnormal properties, it
was possible to quantify their expression. Overall, about
4% of total vessels in controls were constricted compared
with values of 14% in Aβ1−42-injected rat hippocampus and
23.6% in AD brain. It can be noted that other morphological
abnormalities, such as small microvessel fragments, were
evident in diseased tissue. The presence of fragments could
underlie the diminished mean length of microvessels in
AD brain. The altered morphology of microvessels suggests
concomitant changes in cerebral blood ﬂow in intact ani-
mals. Future studies are required to determine the eﬀects of
Aβ1−42 intrahippocampal injection on the hemodynamics of
cerebral blood ﬂow. Recent work using transgenic animals
expressing elevated Aβ1−42 h a sr e p o r t e di m p a i r e dc e r e b r a l
autoregulation of ﬂow which is intact in human AD subjects
[27, 28]. These studies also point out that extrapolation
of animal results to describe similar processes in humans
requires considerable caution.
Overall, this work provides evidence that an animal
model of Aβ1−42 intrahippocampal injection reproduces
some microvessel perturbations which are present in AD
brain. Combined with measurements on BBB dysfunction
[12], the Aβ1−42 animal model has demonstrated eﬃcacy
in simulating prominent vasculature changes evident in
diseased tissue. Future testing of other abnormal processes
characteristic of AD brain such as synaptic dysfunction will
help assess the overall validity of the AD animal model. In
addition, prolonged exposure of brain microenvironments
to Aβ1−42 for durations in excess of 7d will be relevant
to testing the animal model for altered vasculature and
microglial-vascular interactions [16] under conditions of
chronic inﬂammation.
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